BIOXCEL THERAPEUTICS INC. - COMMON STOCK

BioXcel Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

26 May 2021 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II

19 May 2021 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Presentations at the ISBD 2021 Global Annual Conference

11 May 2021 07:00:02 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

10 May 2021 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

04 May 2021 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast

03 May 2021 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Launches “Boiling Point” Educational Campaign to Shed Light on the Importance of Prompt and Cooperative De-escalation in the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders

29 Apr 2021 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Presentations on SERENITY I & II at the 2021 American Psychiatric Association Annual Meeting

26 Apr 2021 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Results of Phase 1b/2 Study of BXCL501 for the Treatment of Opioid Withdrawal Symptoms

31 Mar 2021 16:01:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Receives FDA Breakthrough Therapy Designation for BXCL501 for the Acute Treatment of Agitation Associated with Dementia

15 Mar 2021 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

11 Mar 2021 07:15:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders

11 Mar 2021 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call and Webcast

04 Mar 2021 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics Provides Update on its BXCL501 Program for the Acute Treatment of Dementia Related Agitation

03 Mar 2021 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics Appoints June Bray to Board of Directors

01 Mar 2021 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Initiation of Phase 2 PLACIDITY Trial of BXCL501 for the Treatment of Delirium Related Agitation

25 Feb 2021 07:00:02 By Nasdaq GlobeNewswire

BioXcel Therapeutics Appoints Javier Rodriguez as Chief Legal Officer and Corporate Secretary

23 Feb 2021 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Host Virtual Key Opinion Leader Event to Highlight BXCL501 as a Potential Treatment for Agitation and Opioid Withdrawal Symptoms

12 Feb 2021 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium

04 Feb 2021 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces BXCL501 Met the Primary and All Secondary Endpoints in the TRANQUILITY Phase 1b/2 Study for the Acute Treatment of Agitation in Dementia, including Alzheimer’s Disease

05 Jan 2021 07:00:01 By Nasdaq GlobeNewswire